Form 4: AbbVie Executive Sells Shares Under 10b5-1 Plan

AbbVie's Executive Vice President, General Counsel, and Secretary, Perry C. Siatis, reported the sale of company common stock totaling 18,668 shares under a pre-arranged trading plan.

Summary

• Perry C. Siatis, EVP, GC AND SECRETARY of AbbVie Inc., reported transactions involving company common stock.
• On February 27, 2026, 14,850 shares were disposed of for tax withholding purposes at a price of $232.08 per share.
• On March 2, 2026, a total of 18,668 shares were sold in multiple open market transactions.
• These sales occurred at weighted average prices of $233.51 (5,777 shares), $234.66 (10,291 shares), and $235.26 (2,600 shares).
• Following these transactions, Perry C. Siatis beneficially owns 4,619 shares of AbbVie common stock.
• The transactions were made pursuant to a Rule 10b5-1 pre-arranged trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and personal financial planning, especially given the Rule 10b5-1 plan which mitigates concerns about opportunistic trading.

Negatives

• A significant reduction in direct beneficial ownership by a key executive, from 23,287 shares to 4,619 shares, could be perceived negatively by some investors, despite being pre-planned.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing, as it is solely for reporting insider transactions.

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are common for executives managing their personal portfolios and do not necessarily signal a change in company fundamentals or industry outlook. Such pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information.

Related Party Transactions

• Perry C. Siatis, an Executive Vice President, General Counsel, and Secretary of AbbVie Inc., engaged in transactions involving the company's common stock.

Stakeholder Impact

• Shareholders may note the reduction in direct ownership by a key executive, though the Rule 10b5-1 plan suggests a pre-planned divestment rather than a reaction to new, material information.

Key Dates

Recommendation

The reported transactions are routine insider sales executed under a pre-arranged 10b5-1 plan, which typically do not reflect new material information about the company's prospects. Therefore, these transactions alone do not warrant a change in investment recommendation for AbbVie Inc.

Keywords

AbbVie, ABBV, Form 4, Insider Trading, Stock Sale, Perry C. Siatis, Executive Compensation, Rule 10b5-1, Pharmaceuticals, Biotechnology